{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:22:12Z","timestamp":1791390132550,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012446","name":"Akershus University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012446","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For people with opioid use disorder (OUD), extended-release naltrexone (XR-NTX) is an effective antagonist treatment option. However, successful opioid tapering and abstinence is a prerequisite for XR-NTX induction and has repeatedly been reported as a major barrier to effective treatment. The aims of this study were to describe XR-NTX induction rates, reasons for incomplete induction, and extraordinary complications reported during the induction phase. We also compared sociodemographic and clinical variables among those who did and did not complete induction onto XR-NTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This naturalistic, multicenter, and open-label Norwegian study of XR-NTX included men and women aged 18\u201365 who had severe OUD. Most participants were referred to inpatient medically managed opioid withdrawal and received individualized pharmacological and psychosocial treatment according to clinical assessment and national guidelines. After opioid withdrawal, the participants underwent a minimum of three opioid-free days prior to XR-NTX induction. Variables were collected through baseline assessments and a retrospective patient chart review. XR-NTX induction completers and non-completers were compared via bivariate and logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 129 participants with recent opioid use at inclusion, 106 (82%) completed XR-NTX induction. Induction was initiated in an inpatient setting for 116 participants (90%) and extraordinary complications were noted for 19 (15%) patients. Withdrawal symptoms and ambivalence were the most common reasons for non-completion, each noted in 75% of the cases. As compared with those who successfully completed induction, non-completers more often reported lifetime hepatitis (78% vs. 52%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), had a longer period of current substance use (mean 119 vs. 54 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), and more frequently used methadone prior to study inclusion (43% vs. 8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009001). In logistic regression analyses, methadone use was the only significant factor and was negatively associated with completion (odds ratio 0.20, 95% confidence interval\u2009=\u20090.05\u20130.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results demonstrate the safety, efficacy and tolerability of a Norwegian opioid withdrawal and XR-NTX induction procedure. Although the present induction rate was high, our findings indicate that methadone users need special attention and tailored interventions regarding opioid withdrawal management and XR-NTX induction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The study is registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\" ext-link-type=\"uri\">clinicaltrials.gov<\/jats:ext-link>\n                      (NCT03647774).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00576-9","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T02:39:40Z","timestamp":1750041580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study"],"prefix":"10.1186","volume":"20","author":[{"given":"Jon","family":"Mordal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Juya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-K\u00e5re","family":"Vederhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild","family":"Opheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida H.","family":"Brenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asle E.","family":"Enger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Weimand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Klemmetsby","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"576_CR1","unstructured":"World Drug Report 2024. The United Nations Office on Drugs and Crime, United Nations publication, 2024."},{"issue":"13","key":"576_CR2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","volume":"284","author":"AT McLellan","year":"2000","unstructured":"McLellan AT, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689\u201395.","journal-title":"JAMA"},{"key":"576_CR3","unstructured":"European drug report: trend and developments. 2019, European Monitoring Centre for Drugs and Drug Addiction: Lisbon."},{"issue":"10208","key":"576_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"key":"576_CR5","doi-asserted-by":"crossref","unstructured":"Minozzi S et al. Oral Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev, 2011(4): p. CD001333.","DOI":"10.1002\/14651858.CD001333.pub3"},{"issue":"7","key":"576_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, et al. Extended-release injectable Naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188\u2013209.","journal-title":"Addiction"},{"issue":"1","key":"576_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13722-022-00317-2","volume":"17","author":"A Marciuch","year":"2022","unstructured":"Marciuch A, et al. Patients\u2019 experiences of continued treatment with extended-release Naltrexone: a Norwegian qualitative study. Addict Sci Clin Pract. 2022;17(1):36.","journal-title":"Addict Sci Clin Pract"},{"issue":"12","key":"576_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","volume":"74","author":"L Tanum","year":"2017","unstructured":"Tanum L, et al. Effectiveness of injectable Extended-Release Naltrexone vs daily Buprenorphine-Naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197\u2013205.","journal-title":"JAMA Psychiatry"},{"key":"576_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","volume":"66","author":"LA Uebelacker","year":"2016","unstructured":"Uebelacker LA, et al. Patients\u2019 beliefs about medications are associated with stated preference for methadone, buprenorphine, Naltrexone, or no Medication-Assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016;66:48\u201353.","journal-title":"J Subst Abuse Treat"},{"issue":"10241","key":"576_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","volume":"395","author":"AB Srivastava","year":"2020","unstructured":"Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395(10241):1938\u201348.","journal-title":"Lancet"},{"key":"576_CR11","unstructured":"Alkermes. Vivitrol - Naltrexone for extended release injectable suspension. 2017; Available from: https:\/\/www.vivitrol.com\/"},{"issue":"5","key":"576_CR12","doi-asserted-by":"publisher","first-page":"e249744","DOI":"10.1001\/jamanetworkopen.2024.9744","volume":"7","author":"M Shulman","year":"2024","unstructured":"Shulman M, et al. Rapid initiation of injection Naltrexone for opioid use disorder: A Stepped-Wedge cluster randomized clinical trial. JAMA Netw Open. 2024;7(5):e249744.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"576_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","volume":"174","author":"M Sullivan","year":"2017","unstructured":"Sullivan M, et al. Long-Acting injectable Naltrexone induction: A randomized trial of outpatient opioid detoxification with Naltrexone versus buprenorphine. Am J Psychiatry. 2017;174(5):459\u201367.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"576_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/ajad.12180","volume":"24","author":"S Mogali","year":"2015","unstructured":"Mogali S, et al. Baseline characteristics of patients predicting suitability for rapid Naltrexone induction. Am J Addict. 2015;24(3):258\u201364.","journal-title":"Am J Addict"},{"key":"576_CR15","doi-asserted-by":"publisher","first-page":"109343","DOI":"10.1016\/j.drugalcdep.2022.109343","volume":"233","author":"M Shulman","year":"2022","unstructured":"Shulman M, et al. Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. Drug Alcohol Depend. 2022;233:109343.","journal-title":"Drug Alcohol Depend"},{"key":"576_CR16","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.conctc.2021.100728","volume":"21","author":"BM Weimand","year":"2021","unstructured":"Weimand BM, et al. Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release Naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). Contemp Clin Trials Commun. 2021;21:100728.","journal-title":"Contemp Clin Trials Commun"},{"key":"576_CR17","unstructured":"National practice guidelines for detoxification from legal and illegal substances 2016, The Norwegian Directorate of Health (in Norwegian only)."},{"issue":"4","key":"576_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000259089","volume":"1","author":"A Kokkevi","year":"1995","unstructured":"Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 1995;1(4):208\u201310.","journal-title":"Eur Addict Res"},{"key":"576_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bs.3830190102","volume":"19","author":"LR Derogatis","year":"1974","unstructured":"Derogatis LR, et al. The Hopkins symptom checklist (HSCL): A self-report symptom inventory. Behav Sci. 1974;19:1\u201315.","journal-title":"Behav Sci"},{"issue":"2","key":"576_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S0033291704002892","volume":"35","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, et al. The world health organization adult ADHD Self-Report scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245\u201356.","journal-title":"Psychol Med"},{"key":"576_CR21","doi-asserted-by":"crossref","unstructured":"Brenna IH et al. Patients with opioid use disorder choosing treatment with Extended-Release Naltrexone: A 6-Month naturalistic study. Eur Addict Res, 2024: pp. 1\u201312.","DOI":"10.1159\/000541431"},{"key":"576_CR22","first-page":"5","volume":"25","author":"B Weimand","year":"2023","unstructured":"Weimand B, Solli KAT, Vederhus KK, Mordal J-K, Wergeland Digranes J L., and, Tanum L. Characteristics of opioid-dependent patients choosing antagonist treatment with extended-release Naltrexone compared with patients in opioid maintenance treatment in Norway. Heroin Addict Relat Clin Probl. 2023;25:5\u201314.","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"10118","key":"576_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, et al. Comparative effectiveness of extended-release Naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318.","journal-title":"Lancet"},{"key":"576_CR24","doi-asserted-by":"publisher","first-page":"108292","DOI":"10.1016\/j.jsat.2021.108292","volume":"124","author":"M Shulman","year":"2021","unstructured":"Shulman M, et al. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable Naltrexone induction failure. J Subst Abuse Treat. 2021;124:108292.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"576_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/10550490500528464","volume":"15","author":"MA Sullivan","year":"2006","unstructured":"Sullivan MA, et al. Predictors of retention in Naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict. 2006;15(2):150\u20139.","journal-title":"Am J Addict"},{"issue":"6","key":"576_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000447964","volume":"22","author":"K Sharma Haase","year":"2016","unstructured":"Sharma Haase K, et al. Interest in extended release Naltrexone among opioid users. Eur Addict Res. 2016;22(6):301\u20135.","journal-title":"Eur Addict Res"},{"issue":"1","key":"576_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"PJ Whelan","year":"2012","unstructured":"Whelan PJ, Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45\u201350.","journal-title":"J Neurosci Rural Pract"},{"key":"576_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","volume":"160","author":"BJ Yarborough","year":"2016","unstructured":"Yarborough BJ, et al. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend. 2016;160:112\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"576_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/00333549231222479","volume":"139","author":"JA Dever","year":"2024","unstructured":"Dever JA, et al. The medications for opioid use disorder study: methods and initial outcomes from an 18-Month study of patients in treatment for opioid use disorder. Public Health Rep. 2024;139(4):484\u201393.","journal-title":"Public Health Rep"},{"key":"576_CR30","doi-asserted-by":"crossref","unstructured":"Nesse LL et al. OAT status report., LAR statusrapport 2023. (2023). Norwegian Centre for Addiction Research, University of Oslo; 2024.","DOI":"10.1093\/acrefore\/9780199384655.013.944"},{"key":"576_CR31","first-page":"65","volume":"10","author":"SE Ramsey","year":"2016","unstructured":"Ramsey SE, et al. The need for psychosocial interventions to facilitate the transition to Extended-Release Naltrexone (XR-NTX) treatment for opioid dependence: A concise review of the literature. Subst Abuse. 2016;10:65\u20138.","journal-title":"Subst Abuse"},{"issue":"12","key":"576_CR32","first-page":"CD008063","volume":"12","author":"R Schwenker","year":"2023","unstructured":"Schwenker R, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023;12(12):CD008063.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"576_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13722-025-00548-z","volume":"20","author":"KK Adams","year":"2025","unstructured":"Adams KK, Waters K, Sobieraj DM. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review. Addict Sci Clin Pract. 2025;20(1):19.","journal-title":"Addict Sci Clin Pract"},{"key":"576_CR34","doi-asserted-by":"publisher","first-page":"108667","DOI":"10.1016\/j.jsat.2021.108667","volume":"136","author":"IH Brenna","year":"2022","unstructured":"Brenna IH, et al. Not at all what I had expected\u2019: discontinuing treatment with extended-release Naltrexone (XR-NTX): A qualitative study. J Subst Abuse Treat. 2022;136:108667.","journal-title":"J Subst Abuse Treat"},{"key":"576_CR35","doi-asserted-by":"publisher","first-page":"108183","DOI":"10.1016\/j.jsat.2020.108183","volume":"122","author":"P Gauthier","year":"2021","unstructured":"Gauthier P, et al. Patients\u2019 perspectives on initiating treatment with extended-release Naltrexone (XR-NTX). J Subst Abuse Treat. 2021;122:108183.","journal-title":"J Subst Abuse Treat"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00576-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T02:39:46Z","timestamp":1750041586000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00576-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00576-9","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the South-East Regional Ethical Board for Medical Research Ethics (# 2018\/132), the Norwegian Medicines Agency (EudraCT Code 2017-004706-18), and the Board of Research Ethics at each participating hospital. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki; all participants provided written informed consent before the study began.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written, informed consent for publication in the consent form of the main NaltRec study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}